GlassScriptPhysician profile
Dina M Gibson
NPI 1063998912
$6,277.37
in general payments reported to CMS, 2019-2025
23 companies · $1,775 in 2025
The $1,775 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,394 · 2022: $1,568 · 2023: $493 · 2024: $1,047 · 2025: $1,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,230 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,230.25 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,419.56 | 2021-2025 | Livtencity, Entyvio |
| Gilead Sciences, INC. | $875.16 | 2021-2025 | |
| Abbvie INC. | $852.09 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $807.88 | 2021-2024 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $662.63 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Ipsen Biopharmaceuticals, INC | $313.50 | 2024-2025 | Iqirvo |
| Mallinckrodt Hospital Products INC. | $253.27 | 2022-2025 | Terlivaz |
| Regeneron Healthcare Solutions, INC. | $148.54 | 2022-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $140.62 | 2021 | |
| Qol Medical, LLC | $124.71 | 2021 | |
| Madrigal Pharmaceuticals | $114.88 | 2025 | Rezdiffra |
| Merit Medical Systems INC | $104.26 | 2025 | Esophyx |
| Genzyme Corporation | $79.73 | 2025 | |
| Novo Nordisk INC | $79.03 | 2022 | |
| Histosonics, INC. | $59.16 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $58.35 | 2025 | Zepbound |
| Intercept Pharmaceuticals, INC. | $37.44 | 2022-2023 | Ocaliva |
| Eisai INC. | $30.69 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $28.44 | 2025 | Voquezna |
| Albireo Pharma, INC. | $24.93 | 2023 | Bylvay |
| Travere Therapeutics, INC. | $24.00 | 2022 | |
| W. L. Gore & Associates, INC. | $23.88 | 2023 | Gore Cardioform Septal Occluder |
| Celltrion USA INC. | $14.62 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.